Generation of CD20-specific TCRs for TCR gene therapy of CD20(low) B-cell malignancies insusceptible to CD20-targeting antibodies

Immunotherapy of B-cell leukemia and lymphoma with CD20-targeting monoclonal antibodies (mAbs) has demonstrated clinical efficacy. However, the emergence of unresponsive disease due to low or absent cell surface CD20 urges the need to develop additional strategies. In contrast to mAbs, T-cells via t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Jahn, Lorenz, van der Steen, Dirk M., Hagedoorn, Renate S., Hombrink, Pleun, Kester, Michel G.D., Schoonakker, Marjolein P., de Ridder, Daniëlle, van Veelen, Peter A., Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M.
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2016
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363567/
https://ncbi.nlm.nih.gov/pubmed/27776339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12778
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires